{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:40:05Z","timestamp":1772160005683,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000836","name":"University of Liverpool","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this study was to continually evaluate the association between cardiovascular drug exposure and COVID\u201019 clinical outcomes (susceptibility to infection, disease severity, hospitalization, hospitalization length, and all\u2010cause mortality) in patients at risk of\/with confirmed COVID\u201019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible publications were identified from more than 500 databases on 1 November 2020. One reviewer extracted data with 20% of the records independently extracted\/evaluated by a second reviewer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 52\u2009735 screened records, 429 and 390 studies were included in the qualitative and quantitative syntheses, respectively. The most\u2010reported drugs were angiotensin\u2010converting enzyme inhibitors (ACEIs)\/angiotensin receptor blockers (ARBs) with ACEI\/ARB exposure having borderline association with confirmed COVID\u201019 infection (OR 1.14, 95% CI 1.00\u20131.31). Among COVID\u201019 patients, unadjusted estimates showed that ACEI\/ARB exposure was associated with hospitalization (OR 1.76, 95% CI 1.34\u20132.32), disease severity (OR 1.40, 95% CI 1.26\u20131.55) and all\u2010cause mortality (OR 1.22, 95% CI 1.12\u20131.33) but not hospitalization length (mean difference \u22120.27, 95% CI \u22121.36\u20130.82\u2009days). After adjustment, ACEI\/ARB exposure was not associated with confirmed COVID\u201019 infection (OR 0.92, 95% CI 0.71\u20131.19), hospitalization (OR 0.93, 95% CI 0.70\u20131.24), disease severity (OR 1.05, 95% CI 0.81\u20131.38) or all\u2010cause mortality (OR 0.84, 95% CI 0.70\u20131.00). Similarly, subgroup analyses involving only hypertensive patients revealed that ACEI\/ARB exposure was not associated with confirmed COVID\u201019 infection (OR 0.93, 95% CI 0.79\u20131.09), hospitalization (OR 0.84, 95% CI 0.58\u20131.22), hospitalization length (mean difference \u22120.14, 95% CI \u22121.65\u20131.36\u2009days), disease severity (OR 0.92, 95% CI 0.76\u20131.11) while it decreased the odds of dying (OR 0.76, 95% CI 0.65\u20130.88). A similar trend was observed for other cardiovascular drugs. However, the validity of these findings is limited by a high level of heterogeneity and serious risk of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cardiovascular drugs are not associated with poor COVID\u201019 outcomes in adjusted analyses. Patients should continue taking these drugs as prescribed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.14927","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T17:52:13Z","timestamp":1623174733000},"page":"4534-4545","source":"Crossref","is-referenced-by-count":14,"title":["Cardiovascular drugs and COVID\u201019 clinical outcomes: A living systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-1822","authenticated-orcid":false,"given":"Innocent G.","family":"Asiimwe","sequence":"first","affiliation":[{"name":"The Wolfson Centre for Personalized Medicine, MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  Liverpool L69 3GL UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeep","family":"Pushpakom","sequence":"additional","affiliation":[{"name":"The Wolfson Centre for Personalized Medicine, MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  Liverpool L69 3GL UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Turner","sequence":"additional","affiliation":[{"name":"The Wolfson Centre for Personalized Medicine, MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  Liverpool L69 3GL UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruwanthi","family":"Kolamunnage\u2010Dona","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Institute of Population Health Sciences University of Liverpool  Liverpool L69 3GL UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea L.","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Institute of Population Health Sciences University of Liverpool  Liverpool L69 3GL UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-7266","authenticated-orcid":false,"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[{"name":"The Wolfson Centre for Personalized Medicine, MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool  Liverpool L69 3GL UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.009"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"e_1_2_9_4_1","unstructured":"World Health Organisation.WHO Director\u2010General's opening remarks at the media briefing on COVID\u201019\u201411 March 2020. World Health Organisation.https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Published 11 March2020. Accessed 6 June 2020."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32203-7"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.046941"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104949"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1515"},{"key":"e_1_2_9_10_1","first-page":"1","article-title":"COVID\u201019: Is it time to revisit the research on calcium channel drug targets?","author":"Muthuswamy B","year":"2020","journal-title":"EMJ Diabet"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15166"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14817"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","unstructured":"AsiimweIG PushpakomS TurnerRM Kolamunnage\u2010DonaR JorgensenA PirmohamedM.Cardiovascular drugs and COVID\u201019: a living systematic review and meta\u2010analysis. PROSPERO2020.","DOI":"10.22541\/au.161452914.41833841\/v1"},{"key":"e_1_2_9_14_1","unstructured":"HigginsJPT GreenSE.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.https:\/\/handbook-5-1.cochrane.org\/. Updated March2011. Accessed 1 Juner 2021."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.08.010"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","unstructured":"AsiimweIG PushpakomS TurnerRM Kolamunnage\u2010DonaR JorgensenA PirmohamedM.Cardiovascular drugs and COVID\u201019 clinical outcomes: a living systematic review and meta\u2010analysis.medRxiv preprint.2020.https:\/\/doi.org\/10.1101\/2020.10.07.20208918","DOI":"10.1101\/2020.10.07.20208918"},{"key":"e_1_2_9_17_1","volume-title":"British National Formulary 78 September 2019 \u2013 March 2020","author":"Joint Formulary Committee","year":"2019"},{"issue":"3","key":"e_1_2_9_18_1","first-page":"40","article-title":"meta: an R package for meta\u2010analysis","volume":"7","author":"Schwarzer G","year":"2007","journal-title":"R News"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000696"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"issue":"1","key":"e_1_2_9_23_1","first-page":"S297","article-title":"The Concise Guide to PHARMACOLOGY 2019\/20: Enzymes","volume":"176","author":"Alexander SPH","year":"2019","journal-title":"Br J Pharmacol"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.040"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","unstructured":"DuarteM PelorossoF NicolosiL et al.Telmisartan for treatment of Covid\u201019 patients: an open randomized clinical trial. Preliminary report.medRxiv preprint.2020.","DOI":"10.1101\/2020.08.04.20167205"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1592"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1214\/ss\/1009211805"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.08.004"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2180"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104927"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","unstructured":"Diaz\u2010ArocutipaC Saucedo\u2010ChinchayJ HernandezAV.Association between ACEIs or ARBs use and clinical outcomes in COVID\u201019 patients: a systematic review and meta\u2010analysis.medRxiv.2020.","DOI":"10.1101\/2020.06.03.20120261"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30558-0"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14927","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14927","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:58:38Z","timestamp":1693184318000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/bcp.14927"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14927","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.07.20208918","asserted-by":"object"}]},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]}}}